• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of Cancer Research and Treatment >3-bromopyruvate as a Promising Treatment for Hematological Cancer
【24h】

3-bromopyruvate as a Promising Treatment for Hematological Cancer

机译：3-溴丙酮酸盐作为血液学癌症的有希望的治疗方法

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Many biological differences exist between cancer cells and normal cells that can act as potential targets in targeted cancer therapy. Hematological cancers e.g. lymphoma, leukemia and myeloma exhibit drug-resistance that ultimately results in deteriorated patients' conditions and high mortality rates. Resistance of hematological malignancy to conventional chemotherapy is attributed in part to upregulation of glucose oxidation (glycolysis) genes evidenced by gaining a promising chemosensitization effect upon adding a glycolysis inhibitor to chemotherapeutics. The promising anticancer agent 3-bromopyruvate (3BP) is a structural analog of both pyruvate and lactate. 3BP was reported to antagonize the Warburg effect (malignant phenotype where cancer cells utilize cytoplasmic glucose oxidation to produce ATP and lactate even in the presence of oxygen without making benefit of the generous ATP provision from glucose oxidation via mitochondrial pathways). Warburg effect deprives cancer cells from the high energetic yield achieved through utilizing mitochondrial pathways. 3BP is a promising antiglycolytic agent that targets major glycolysis enzymes (hexokinase II and glyceraldehyde-3-phosphate dehydrogenase. In this article, 3BP promising anticancer effects in treating lymphoma, leukemia and myeloma are discussed in addition to the mode of inhibition of Warburg effect using 3BP. In conclusion, 3BP is a promising anticancer drug (that will be more powerful upon proper pharmaceutical formulations) for treating hematological malignancies. 3BP is advisable to be included in treatment protocols in hematological cancers as a chemosensitizer or as a sole anticancer agent.
机译：癌细胞与正常细胞之间存在许多生物学差异，可以作为靶向癌症治疗中的潜在靶标。血液系统癌症淋巴瘤，白血病和骨髓瘤表现出耐药性，最终导致患者病情恶化和高死亡率。血液恶性肿瘤对常规化学疗法的抗性部分归因于葡萄糖氧化（糖酵解）基因的上调，这通过在将糖酵解抑制剂添加到化学疗法中时获得有希望的化学增敏作用来证明。有前途的抗癌药3-溴丙酮酸（3BP）是丙酮酸和乳酸的结构类似物。据报道3BP拮抗Warburg效应（恶性表型，癌细胞利用胞质葡萄糖氧化即使在有氧条件下也利用胞质葡萄糖氧化产生ATP和乳酸盐，而没有利用线粒体途径从葡萄糖氧化中获得的大量ATP供给）。沃堡效应使癌细胞无法通过利用线粒体途径获得高能量。 3BP是针对主要糖酵解酶（己糖激酶II和3-磷酸甘油醛脱氢酶）的有前途的抗糖酵解剂。在本文中，除了使用Warburg效应抑制模式外，还讨论了3BP在治疗淋巴瘤，白血病和骨髓瘤方面有希望的抗癌作用。 3BP。总之，3BP是用于治疗血液恶性肿瘤的有前途的抗癌药物（在适当的药物制剂中会更有效），建议将3BP作为化学增敏剂或单独的抗癌剂纳入血液癌症的治疗方案中。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号